EC Number   |
Inhibitors |
Structure |
|---|
    2.1.1.37 | (-)-epigallocatechin-3-gallate |
competitive, the inhibitor can form hydrogen bonds with Pro1223, Glu1265, Cys1225, Ser1229 and Arg1309. Hypermethylation of CpG islands in the promoter regions is an important mechanism to silence the expression of many important genes in cancer. (-)-Epigallocatechin-3-gallate can inhibit DNMT activity and reactivate methylation-silenced genes in cancer cells |
   |
| 2.1.1.37 | (N4-fluoroacetyl-5-azacytidine) |
efficient inhibitor of DNA methylation in human tumor cell lines |
|
| 2.1.1.37 | 2'-dC |
binding modelling, overview |
|
| 2.1.1.37 | 2'-deoxy-5-aza-cytidine |
binding modelling, overview |
|
| 2.1.1.37 | 2-(1H)-pyrimidinone riboside |
i.e. zebularine, is a more stable, less cytotoxic inhibitor compared to 5-azacytidine probably due to differing stability and reversibility of the covalent bonds. The ternary complexes between the enzyme, 2-(1H)-pyrimidinone inhibitor, and the cofactor S-adenosyl-L-methionine are maintained through the formation of a reversible covalent interaction |
|
| 2.1.1.37 | 2-amino-4-([[(2S,3S,4R,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl]sulfanyl)butanoic acid |
- |
|
| 2.1.1.37 | 2-amino-4-([[(2S,3S,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl]sulfanyl)butanoic acid |
- |
|
| 2.1.1.37 | 2-amino-4-([[(2S,3S,4R,5R)-5-(6-amino-2-iodo-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl]sulfanyl)butanoic acid |
- |
|
| 2.1.1.37 | 2-amino-4-([[(2S,3S,4R,5R)-5-(6-amino-2-methoxy-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl]sulfanyl)butanoic acid |
- |
|
| 2.1.1.37 | 2-amino-4-([[(2S,3S,4R,5R)-5-(6-amino-2-methyl-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl]sulfanyl)butanoic acid |
- |
|
